Unlike honokiol, EGFR tyrosine kinase inhibitors erlotinib and gefitinib impair the regeneration of normal pulmonary epithelial cells [38–41] through the blockade of EGFR-dependent phosphorylation, and therefore this group of drugs is commonly incriminated as etiologies of interstitial lung disease, a lung-specific toxicity arising in NSCLC patients receiving these drugs. Here, EGFR is linked to non-small cell lung carcinoma.